The long term effects of sulphasalazine in the treatment of rheumatoid arthritis and a comparative study with penicillamine.

The long term efficacy and tolerability of sulphasalazine (SASP) in the treatment of 21 patients with active classical or definite rheumatoid arthritis (RA) were examined and compared with the effects of penicillamine in a similarly active group of RA patients. Nineteen of the 21 patients treated with SASP improved during the first 6 months as shown by significant changes in the clinical and laboratory variables. Clinical improvement was maintained for the remainder of the year.

Synovial fluid and plasma fibronectin levels in rheumatoid arthritis.

1. Plasma fibronectin levels were similar in 60 healthy subjects and 88 with the rheumatoid arthritis. 2.

Rheumatoid arthritis: effects of a new agent (ICI 55 897) on serum acute phase proteins and the erythrocyte sedimentation rate.

Thirty-four patients with rheumatoid arthritis (RA) were treated with a new agent (ICI 55 897) in addition to basic therapy with nonsteroid anti-inflammatory drugs. Five patients had the drug for less than 28 days; the remaining 29 were observed for periods up to a year. At 140 days, when all but 2 patients were in the study, there had been statistically significant improvement in clinical score, serum C-reactive protein, erythrocyte sedimentation rate, and plasma fibrinogen.

Effects of gold, dapsone, and prednisone on serum C-reactive protein and haptoglobin and the erythrocyte sedimentation rate in rheumatoid arthritis.

Sequential measurements of serum C-reactive protein (CRP), serum haptoglobin (Hp), and erythrocyte sedimentation rate (ESR) were made in 209 patients with rheumatoid arthritis (RA); 78 of them were treated with gold, 71 with dapsone, and 60 with prednisone. The results were expressed as proportional changes in the measurements at 28-day intervals after treatment began. The period of study was 140 days.